I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Gary Evans Biography and Net Worth

Director of Novavax

Gary C. Evans is an Independent Director of Novavax, Inc. Mr. Evans is Chairman of the Board and Chief Executive Officer of Generation Hemp, Inc. since 2019, and prior to that Chairman of the Board and Chief Executive Officer of Energy Hunter Resources, Inc., a Dallas based oil and gas exploration and production company, from May 2016 to November 2019. From May 2009 until May 2016, Mr. Evans served as Chairman of the Board and Chief Executive Officer of Magnum Hunter Resources Corporation (“Magnum Hunter”). In December 2015, Magnum Hunter filed for Chapter 11 bankruptcy and exited restructuring in May 2016 under Mr. Evans’ leadership. Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, Magnum Hunter Resources Inc., Wind Hunter Energy, LLC, and GreenHunter Energy, Inc. Mr. Evans was inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. He was also recognized as the Energy Industry Leader of the year in 2013 and chosen by Finance Monthly in 2013 as one of the most respected CEO’s. Mr. Evans was chosen as the Best CEO in the “Large Company” category by Texas Top Producers in 2013 and won the Deal Maker of the Year Award in 2013 by Finance Monthly. Mr. Evans serves as a member of the board of directors of Generation Hemp, Inc., and on the Advisory Board of the Maguire Energy Institute at Southern Methodist University.

What is Gary C. Evans' net worth?: The estimated net worth of Gary C. Evans is at least $8.14 million as of January 18th, 2023. Mr. Evans owns 935,781 shares of Novavax stock worth more than $8,141,295 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Evans may own. Learn More about Gary C. Evans' net worth.
How do I contact Gary C. Evans?: The corporate mailing address for Mr. Evans and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on Gary C. Evans' contact information.
Has Gary C. Evans been buying or selling shares of Novavax?: Gary C. Evans has not been actively trading shares of Novavax over the course of the past ninety days. Most recently, Gary C. Evans sold 24,500 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $211.21, for a transaction totalling $5,174,645.00. Following the completion of the sale, the director now directly owns 18,099 shares of the company's stock, valued at $3,822,689.79. Learn More on Gary C. Evans' trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 62,312 shares worth more than $866,211.80. The most recent insider tranaction occured on June, 21st when Director James F Young sold 7,500 shares worth more than $105,675.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 6/21/2024.

Gary C. Evans Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2021	Sell	24,500	$211.21	$5,174,645.00	18,099
6/6/2016	Sell	18,998	$6.50	$123,487.00	321,979
5/24/2016	Sell	50,000	$5.41	$270,500.00	357,111
8/24/2015	Sell	20,000	$11.24	$224,800.00	340,977
8/13/2015	Sell	6,002	$13.56	$81,387.12
12/16/2014	Sell	46,701	$5.72	$267,129.72
12/12/2014	Sell	30,000	$5.77	$173,100.00

Gary C. Evans Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $8.70

$8.37

$8.89

50 Day Range

MA: $9.13

$7.22

$12.62

2 Week Range

Now: $8.70

$3.53

$23.86

Volume

6,086,848 shs

Average Volume

9,218,745 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW